APLT Applied Therapeutics, Inc.

Healthcare [ 3/11 ] | Biotechnology [ 47/154 ]

US | NASDAQ | Stock

Price: $1.21

Increased by +6.14%
Dollar Volume: 300.35 K
ADR%: 11.34
Earnings Report Date (estimate): Mar 8, 23 (-0.4)

Market Cap.: 58.15 M
Shares Float: 28.24 M
Shares Outstanding: 48.06 M

Beta: 1.75
Price / Earnings: -0.30
BPR: 76.03

20D Range: 0.70 1.24
50D Range: 0.70 1.25
200D Range: 0.50 2.22

Quarterly Earnings
Annual Earnings

Reported Date	EPSChange YoY	EstimateSurprise
Nov 9, 22	-0.40 Increased by +63.30%	-0.48 Increased by +16.67%
Aug 12, 22	-0.96 Increased by +3.03%	-0.78 Decreased by -23.08%
May 12, 22	-0.88 Increased by +12.00%	-0.83 Decreased by -6.02%
Mar 10, 22	-1.04 Increased by +1.89%	-1.25 Increased by +16.80%
Nov 12, 21	-1.09 Increased by +18.05%	-1.16 Increased by +6.03%
Aug 12, 21	-0.99 Increased by +22.05%	-1.13 Increased by +12.39%
May 11, 21	-1.00 Decreased by -69.49%	-1.01 Increased by +0.99%
Mar 18, 21	-1.06 Increased by +32.48%	-1.25 Increased by +15.20%

Quarterly Financials
Annual Financials

Fiscal ending date	RevenueChange YoY	IncomeChange YoY	ProfitChange YoY
Sep 30, 22	0.00 Decreased by N/A%	-19.10 M Increased by +32.79%	Decreased by N/A% Decreased by N/A%
Jun 30, 22	0.00 Decreased by N/A%	-25.86 M Decreased by -0.11%	Decreased by N/A% Decreased by N/A%
Mar 31, 22	0.00 Decreased by N/A%	-23.12 M Increased by +4.38%	Decreased by N/A% Decreased by N/A%
Dec 31, 21	0.00 Decreased by N/A%	-27.16 M Decreased by -14.65%	Decreased by N/A% Decreased by N/A%
Sep 30, 21	0.00 Decreased by N/A%	-28.42 M Increased by +4.78%	Decreased by N/A% Decreased by N/A%
Jun 30, 21	0.00 Decreased by N/A%	-25.83 M Increased by +7.95%	Decreased by N/A% Decreased by N/A%
Mar 31, 21	0.00 Decreased by N/A%	-24.18 M Decreased by -95.48%	Decreased by N/A% Decreased by N/A%
Dec 31, 20	0.00 Decreased by N/A%	-23.69 M Decreased by -34.34%	Decreased by N/A% Decreased by N/A%

Top 20 ETF Stock Exposure
Top 20 Institutional Holders
Top 20 Mutual Fund Holders

Rank	ETF	Shares	Market Value	Weight % in ETF

DAILY

WEEKLY

MONTHLY

Applied Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel products to target cardiovascular disease, galactosemia, and diabetic complications. Its lead product candidate is AT-007 that has completed phase 1/2 for the treatment of galactosemia in healthy volunteers and adults, as well as is in pediatric clinical study for the treatment of galactosemia in kids; for treating sorbitol dehydrogenase deficiency; and for the treatment of phosphomannomutase enzyme-CDG. The company also develops AT-001 that is in phase III clinical trials for treating diabetic cardiomyopathy, as well as for the treatment of diabetic peripheral neuropathy. Its preclinical stage products include AT-003 for the treatment diabetic retinopathy; AT-104, a PI3K inhibitor for treating orphan hematological oncology T Cell Acute Lymphoblastic Leukemia. Applied Therapeutics, Inc. was incorporated in 2016 and is headquartered in New York, New York.